Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Heart Failure

Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Heart Failure c CAPSULES | CLINICAL MATTERS Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Heart Failure Diabetes (DM) and heart failure (HF) are chronic Recent randomized, placebo-controlled The ADA Standards conditions that often coexist, and each condition trials have provided important evidence on of Care currently is a risk factor for the other. The prevalence of the benefi ts of sodium-glucose cotransporter type 2 diabetes (T2D) ranges from 10% to 47% 2 (SGLT2) inhibitors on HF outcomes and recommends in studies evaluating populations with a history infl uenced recommendations from societies metformin as fi rst- of HF with reduced fraction (HFrEF) or HF with such as the American Diabetes Association (ADA) 1-3 line therapy in all preserved ejection fraction (HFpEF). In people and American College of Cardiology (ACC). The with DM, the prevalence of HF is between 9% and ADA Standards of Care currently recommends people with T2D 22%, which is 4 times higher than the general metformin as fi rst-line therapy in all people with but supports the 4 population. Several classes of medications have T2D but supports the additional use of an SGLT2 proven mortality benefi t in HF, including beta- inhibitor with demonstrated benefi t in those http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png ADCES in Practice SAGE

Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Heart Failure

ADCES in Practice , Volume 9 (6): 5 – Nov 1, 2021

Loading next page...
 
/lp/sage/sodium-glucose-cotransporter-2-inhibitors-for-the-treatment-of-heart-SjuB8yD6j3
Publisher
SAGE
Copyright
© 2021 by the American Association of Diabetes Educators
ISSN
2633-559X
eISSN
2633-5603
DOI
10.1177/2633559x211034488
Publisher site
See Article on Publisher Site

Abstract

c CAPSULES | CLINICAL MATTERS Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Heart Failure Diabetes (DM) and heart failure (HF) are chronic Recent randomized, placebo-controlled The ADA Standards conditions that often coexist, and each condition trials have provided important evidence on of Care currently is a risk factor for the other. The prevalence of the benefi ts of sodium-glucose cotransporter type 2 diabetes (T2D) ranges from 10% to 47% 2 (SGLT2) inhibitors on HF outcomes and recommends in studies evaluating populations with a history infl uenced recommendations from societies metformin as fi rst- of HF with reduced fraction (HFrEF) or HF with such as the American Diabetes Association (ADA) 1-3 line therapy in all preserved ejection fraction (HFpEF). In people and American College of Cardiology (ACC). The with DM, the prevalence of HF is between 9% and ADA Standards of Care currently recommends people with T2D 22%, which is 4 times higher than the general metformin as fi rst-line therapy in all people with but supports the 4 population. Several classes of medications have T2D but supports the additional use of an SGLT2 proven mortality benefi t in HF, including beta- inhibitor with demonstrated benefi t in those

Journal

ADCES in PracticeSAGE

Published: Nov 1, 2021

There are no references for this article.